Altana advises the shareholders of Biofides et A.R.C. Pharma in their acquisition by the Pharmalex group.

Paris, April 24, 2018

Altana advised all of the shareholders of the French companies Biofides and A.R.C. Pharma as part of the sale of the totality of  share capital and the voting rights of Biofides and A.R.C. Pharma to Pharmalex France, subsidiary of the German company Pharmalex GmbH.

Biofides is the parent company of A.R.C. Pharma, a consulting, information and assistance company who has specialized in pharmaceutical regulatory affairs for over 30 years.

Pharmalex is a global leader in regulatory affairs consulting, in quality management, compliance and  pharmacovigilance as well as in business development for the pharmaceutical industry.

Altana represented the sellers, namely the majority shareholder and his children on one part and the minority shareholder operations managers on the other part.

For the German acquirer, financed by Auctus Capital Partners AG and present on every continent, this transaction is part of a build-up strategy and extension in terms of geographic coverage.

The management of the French entity will be entrusted to Sophie Guillaume, who already represented Pharmalex in France prior to this key acquisition for the group.

Through this transaction, Altana once again demonstrates the firm's expertise in the life sciences domain and its strong position on cross-border transactions.

Consel of the shareholders of Biofides and A.R.C. Pharma

Altana, with Jean-Nicolas Soret (Partner) and Vincent Guilaine.

Counsel of Pharmalex France

Rödl, with Anne-Sophie Hébras for the legal aspectsa and Maximilian Egger for the financial aspects.